<DOC>
	<DOC>NCT00048711</DOC>
	<brief_summary>The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)</brief_summary>
	<brief_title>Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis VI</mesh_term>
	<criteria>Patient consent Patient must be five years of age or older Patient must have documented biochemical or genetic proof of MPS VI Patient must walk at least 1 meter, but less than 250 meters, in the first 6 minutes of the baseline 12minute walk test If female of childbearing potential, patient must have a negative pregnancy test Patient is under consideration for or has undergone a successful bone marrow transplant (BMT). Pregnant or lactating patient Patient has received an investigational drug within 30 days prior to study enrollment Patient has been previously treated with rhASB Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance Patient has a known hypersensitivity to rhASB or to components of the study drug History of cancer (except low grade and fully resolved skin malignancy)</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>